PGT-A
Screens embryos for the right number of chromosomes before transfer.
- Sample
- Trophectoderm biopsy (day 5-6 blastocyst)
- Method
- Next-generation sequencing (24-chromosome)
- Price
- On request
About this test
Screens all 24 chromosomes for whole-chromosome aneuploidy to identify euploid embryos.
What the report contains
Euploid/aneuploid call per embryo with chromosome copy-number and any mosaicism flag.
Evidence and limitations
PGT-M and PGT-SR are well-established for monogenic disease and structural rearrangements. PGT-A and non-invasive PGT-A are best used selectively, with the clearest signal in older patients per transfer.
Limitations
Randomised trials have not shown PGT-A to improve cumulative live birth in unselected patients: it selects between existing embryos rather than improving them. niPGT-A from spent culture medium is investigational, and its concordance with trophectoderm biopsy varies between laboratories.
Ordering and consent
This test needs genetic counselling and written consent; your clinic confirms both at ordering.
More in Embryo testing (PGT)
- PGT-SR
For carriers of chromosome rearrangements; finds the balanced embryos.
- Non-invasive PGT-A (niPGT-A)
Chromosome screening from the embryo’s culture fluid, used alongside, not instead of, biopsy PGT-A.
Register your clinic
Registration includes onboarding and training for your team. We reply within two working days.